Showing 5581-5590 of 5838 results for "".
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Pycnogenol Improves Visible Signs of Aginghttps://practicaldermatology.com/news/20120718-pycnogenol_improves_visible_signs_of_aging/2459770/Pycnogenol is effective in improving visible signs of skin aging in women aged 55 to 68 years, according to a study published in a recent issue of Skin Pharmacology and Physiology. The study found that after 12 weeks of supplementing with Pycno
- CellCeuticals Nominated for Cosmetic Innovation Awardhttps://practicaldermatology.com/news/20120629-cellceuticals_nominated_for_cosmetic_innovation_award/2459777/CellCeuticals Skin Care, Inc., Biomedical Skin Treatments was named a finalist in two categories by the Independent Cosmetic Manufacturers and Distributors Association (ICMAD). InterActive Moisture Serum 2 was nominated for Best Skin Care P
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Stiefel, a GSK Company, Acquires Worldwide Rights to Toctino (alitretinoin)https://practicaldermatology.com/news/20120612-stiefel_a_gsk_company_acquires_worldwide_rights_to_toctino_alitretinoin/2459784/Stiefel, a GSK company, has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. A once-daily oral retinoid, Toctino is in Phase 3 trials in the US, where it has not yet received FDA approval. Globally, it is the only prescription medicine specifically
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w